Yarrow Bioscience Announces Closing of Merger with VYNE Therapeutics and Initiation of Dosing in Phase 2a/2b Trial of YB-101, a Potential First-in-Class Treatment for Graves’ Disease and Thyroid Eye Disease
Business Wire•27/07/2026•07:00 ET
0
Whiz Insights
Get started
Create a free account to read the full story.